|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 01/09/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 01/01/2023 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 04/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 26/08/2016 |
Günter von Au
CHM | Chairman | 75 | 27/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +2.70% | +0.35% | +40.67% | +110.31% | 1,032B | ||
| +1.44% | -3.41% | +37.36% | +63.95% | 614B | ||
| +1.75% | +3.07% | +17.89% | +83.05% | 471B | ||
| +0.60% | -4.35% | +60.80% | +37.46% | 350B | ||
| +2.92% | +3.06% | +24.83% | +45.10% | 337B | ||
| +2.42% | -0.74% | +13.44% | +35.80% | 268B | ||
| +1.86% | -0.81% | -4.69% | +12.20% | 246B | ||
| +2.60% | -2.49% | +40.45% | +54.44% | 218B | ||
| +1.82% | -2.93% | +29.29% | +96.48% | 179B | ||
| Average | +1.12% | -3.24% | +28.89% | +59.87% | 372.06B | |
| Weighted average by Cap. | +0.69% | -3.18% | +32.16% | +70.59% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















